Studies
Pan Cancer
- FGFR
Lung Cancer
NSCLC
- Association between BRAF mutation class and clinical features in BRAF mutant NSCLC
- EGFR mutant NSCLC treated with EGFR tyrosine kinase inhibitors
- EGFR L747P Gefitinib and Osimeritinib (Lung adenocarcinoma)
- ALK G1202L associated with lung adenocarcinoma, Loralatinib
- EGFR activating mutation T790M/cis-C797S triple mutations for lung adenocarcinoma, brigatinib + cetuximab in combination
- c-Met Exon 14 Skipping mutations, crizotinib (295 panel)
- Malignant pleural mesothelioma- multiple mutations including ALKI1171N, ALKL1196M, ALKG1202R, lorlatinib being measured in EML4-ALK rearranged malignant pleural mesothelioma
- RET rearrangement
- pulmonary adenoid cystic carcinoma
- pulmonary blastoma harboring CD74 ROS1 fusion, response to crizotinib
Endometrial Cancer
- afatinib in HER2 positive endometrioid adenocarcinoma
Colorectal cancer (295 panel)
- somatic pole exonuclease domain mutations
Gallbladder cancer
- AMBER1 - ALK fusion, crizotinib
Breast cancer
- metastatic breast cancer
- HER2 positive breast cancer, heterogeneity of genomic profile
- BRCA vs NonBRCA germline and somatic mutations
Cervical
- EGFR amplification cervical squamous cell carcinoma with pulmonary metastasis, afatinib
- metastatic cervical carcinoma with high-TMB, exceptional response of cryo ablation followed by pembrolizumab
Metastasis
- mutational signal of double primary malignancies
Brain Cancer
- pleomorphic xanthoastrocytoma
Metastatic Nasopharyngeal Carcinoma
- CDK4 amplification, palbociclib